Background—Diffuse myocardial fibrosis is a final end point in most cardiac diseases. It is
missed by the cardiovascular magnetic resonance (CMR) late gadolinium enhancement …

Abstract Background Gadolinium (Gd) Extracellular volume fraction (ECV) by
Cardiovascular Magnetic Resonance (CMR) has been proposed as a non-invasive method …

Aims Haemodynamics alone do not fully explain symptoms and prognosis in clinically
severe aortic stenosis (AS). Myocardial disease, specifically diffuse myocardial fibrosis …

Background Myocardial extravascular extracellular volume fraction (Ve) measures quantify
diffuse fibrosis not readily detectable by conventional late gadolinium (Gd) enhancement …

Objectives: The purpose of this study was to investigate a noninvasive method for
quantifying diffuse myocardial fibrosis with cardiac magnetic resonance imaging (CMRI) …

Background Aortic stenosis (AS) leads to diffuse fibrosis in the myocardium, which is linked
to adverse outcome. Myocardial T1 values change with tissue composition. Objective To test …

Aim Myocardial fibrosis is fundamental in the pathogenesis of heart failure. Late gadolinium
enhancement (LGE) with cardiac magnetic resonance (CMR) imaging is commonly …

Background Cardiac magnetic resonance (CMR) T1 mapping has been used to characterize
myocardial diffuse fibrosis. The aim of this study is to determine the reproducibility and …

Background The availability of a non-invasive test to detect and quantify interstitial and
replacement fibrosis would be a useful advance for evaluation of cardiac therapies that …

Diffuse interstitial or replacement myocardial fibrosis is a common feature of a broad variety
of cardiomyopathies. Myocardial fibrosis leads to impaired cardiac diastolic and systolic …